Assessing real-world outcomes of abemaciclib in breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the real-world clinical outcomes and adverse events associated with the use of abemaciclib in combination with endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer. Following the FDA's approval of abemaciclib for adjuvant treatment, the study will gather data on efficacy and toxicity in both advanced and early breast cancer settings. Patients will report their side effects through a dedicated online platform, where they will be randomized into two arms to receive different levels of support based on their reports. The study aims to enhance understanding of treatment experiences in a real-world context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed HR-positive, HER2-negative breast cancer
* Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
* 18 years or older
* Any menopausal status
* Treatment with abemaciclib in combination with endocrine therapy
* Any endocrine therapy
* At least two months of treatment with abemaciclib

Where it's running

• Hellenic Oncology Cooperative Group
  Athens, Greece Recruiting

Study contacts

• Study coordinator: Elena Fountzilas, MD, PhD
• Email: FOUNTZILA@ONCOGENOME.GR
• Phone: +306945779709

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.